Indian pacing and electrophysiology journal · 2026
Think SCN5A: A novel variant causing multifocal Purkinje PVCs and dilated cardiomyopathy.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hanna Daniel B, Kossack Andrew, Perez-Hernandez Juan, Venn Rachael, Rechani Luis, Sublette Samantha, Navas Viviana, Sharma Dinesh
Аннотация
BACKGROUND: Multifocal ectopic Purkinje-related premature contractions (MEPPC) represent a rare SCN5A-associated channelopathy characterized by high-burden, multifocal premature ventricular contractions (PVCs) arising from the His-Purkinje system, often leading to reversible left ventricular dysfunction.
CASE SUMMARY: We describe a young male with a MEPPC-like phenotype and a novel SCN5A (c.655G > A, p.Arg222Gln) variant presenting with multifocal Purkinje and papillary muscle PVCs and left ventricular systolic dysfunction. Sequential focal ablations reduced the dominant ectopic burden, while adjunctive flecainide therapy further suppressed residual Purkinje activity and improved ventricular function.
CONCLUSION: In young patients with multifocal Purkinje PVCs and unexplained cardiomyopathy, consider SCN5A mutation. Combined ablation and sodium-channel blockade could be considered as a treatment option.
CASE SUMMARY: We describe a young male with a MEPPC-like phenotype and a novel SCN5A (c.655G > A, p.Arg222Gln) variant presenting with multifocal Purkinje and papillary muscle PVCs and left ventricular systolic dysfunction. Sequential focal ablations reduced the dominant ectopic burden, while adjunctive flecainide therapy further suppressed residual Purkinje activity and improved ventricular function.
CONCLUSION: In young patients with multifocal Purkinje PVCs and unexplained cardiomyopathy, consider SCN5A mutation. Combined ablation and sodium-channel blockade could be considered as a treatment option.